Quizartinib + Treatment according to Physician's Choice + Standard of Care Chemotherapy
Phase 3Withdrawn 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Myeloid Leukemia
Conditions
Acute Myeloid Leukemia
Trial Timeline
May 1, 2022 → Dec 1, 2025
NCT ID
NCT04676243About Quizartinib + Treatment according to Physician's Choice + Standard of Care Chemotherapy
Quizartinib + Treatment according to Physician's Choice + Standard of Care Chemotherapy is a phase 3 stage product being developed by Daiichi Sankyo for Acute Myeloid Leukemia. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT04676243. Target conditions include Acute Myeloid Leukemia.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04676243 | Phase 3 | Withdrawn |
Competing Products
20 competing products in Acute Myeloid Leukemia